Chemotherapy stands out as the main systemic treatment strategy against cancer
and still faces problems related to multidrug resistance and severe side
effects. Copper-based drugs have been widely ...explored in medicinal chemistry,
since copper is an essential metal for physiological activities with
antineoplastic effects. In this context, the present study aimed to evaluate the
recombinogenic/mutagenic and anticarcinogenic potential of the complex CBP-01 -
Cu(bta)(1,10-phen)ClO
4
(Hbta =
4,4,4-trifluoro-1-phenyl-1,3-butanedione and 1,10-phen =1,10-phenanthroline) -
through the Somatic and Recombination test (SMART) and the Epithelial Tumor Test
(ETT) in
Drosophila melanogaster
, compared with carboplatin
(CARB) and cisplatin (CIS) effects. According to our results, CARB and CIS
induced a high frequency of mutant spots, which was not verified at higher
concentrations of CBP-01. In addition, CBP-01 exhibited mutagenic/recombinogenic
potential only at the lowest concentration and after biometabolization.
Subsequently, in the ETT test, CBP-01 did not demonstrate carcinogenic effect.
Lastly, epithelial tumors were identified in flies treated with CARB and CIS,
which were modulated by the CBP-01 complex. Therefore, CBP-01 modulates
genotoxicity of other compounds and is a promising metal-based drug for the
development of a new anticancer agent or for optimization of therapeutic
regimens.
PDF
